Core Insights - LENZ Therapeutics has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting for the commercialization of VIZZ in the Middle East, which includes revenue sharing and milestone payments [1][2][3] Company Overview - LENZ Therapeutics is focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved eye drop for presbyopia, impacting approximately 1.8 billion people globally and 128 million in the U.S. [9] - Lunatus is a Dubai-based pharmaceutical company specializing in the commercialization of healthcare products in the Middle East, established in 2003 [10] Product Information - VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing aceclidine as the active ingredient [5] - The product is preservative-free and provided in single-dose vials, offering a pupil-selective miotic effect to improve vision [5] Market Context - The partnership with Lunatus represents LENZ's fourth commercialization partnership for VIZZ, aimed at expanding access to presbyopia treatment in key strategic regions [3] - Presbyopia affects nearly all individuals over the age of 45, with adults over 50 losing an average of 1.5 lines of near vision every six years [4]

®2®3 PLAINSBORO, N.J.and BAGSVÆRD, Denmark, Jan. 5, 2026 /PRNewswire/ -- Wegovy pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity. Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-rel ...

Core Insights - Crinetics Pharmaceuticals reported unaudited and preliminary net product revenue of over $5 million for PALSONIFY in the fourth quarter of 2025, with over 200 enrollment forms submitted by the end of December [2][4][5] - Positive topline results from the fourth cohort of the Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant were announced, showing a 67% mean reduction in androstenedione levels and enabling 88% of participants to successfully reduce glucocorticoid doses to physiological levels [1][8][9] Company Performance - The launch of PALSONIFY, approved by the FDA on September 25, 2025, has been characterized by strong execution, with over 200 enrollment forms and a broad prescriber base [3][4][7] - Feedback from patients, physicians, and payers has been positive, leading to early formulary inclusions by payers [4][5] Clinical Study Results - The fourth cohort of the Phase 2 TouCAHn trial involved 10 patients with classic CAH, with treatment resulting in significant reductions in androstenedione levels [5][8] - Atumelnant was well-tolerated, with no serious adverse events reported, and a favorable benefit/risk profile maintained throughout the study [11][14] Future Outlook - Crinetics plans to host an investor conference call to discuss the topline results from the study, indicating ongoing engagement with investors and stakeholders [15][16] - Atumelnant is positioned as a potential transformational treatment for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with ongoing Phase 3 clinical development [17][20]

Core Viewpoint - Novo Nordisk has launched the first-ever GLP-1 oral pill for weight loss in the U.S., marking a significant advancement in obesity treatment [1][2]. Pricing and Accessibility - The cash prices for the Wegovy pill range from $149 to $299 per month, depending on the dosage, which aims to address affordability issues associated with existing weekly injection treatments [2][4]. - The starting dose of 1.5 milligrams is available at over 70,000 U.S. pharmacies and select telehealth providers, with higher doses expected to be available shortly [3]. - Patients with insurance can access the drug for as low as $25 per month, while cash-paying patients can also purchase it through a deal with TrumpRx for $149 per month [4][5]. Market Potential - The GLP-1 market is projected to be worth approximately $100 billion by the 2030s, with oral drugs potentially capturing a 24% market share, equating to around $22 billion [7]. - Novo Nordisk's launch gives it a competitive edge as it awaits FDA approval for a rival pill from Eli Lilly later this year [8]. Clinical Efficacy - In a phase three trial, the highest dose of the oral semaglutide led to an average weight loss of 16.6% after 64 weeks, with a 13.6% weight loss observed across all participants [11]. - The Wegovy pill is reported to be slightly more effective than Eli Lilly's experimental oral drug, which does not impose dietary restrictions [12]. Regulatory Approval - The FDA approved the Wegovy pill for weight loss and for reducing the risk of major cardiovascular events in adults with obesity and established cardiovascular disease [8][9].

Group 1 - The company Incyte announced that its experimental combination therapy successfully met the primary endpoint in a late-stage trial for patients with a specific type of blood cancer [1]

PASADENA, Calif.-(BUSINESS WIRE)---- Sarwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLOâ, ¢ (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 ti. ...

Group 1 - Corbus Pharmaceuticals Holdings Inc. is a clinical-stage company focused on oncology and obesity, with a commitment to innovative scientific approaches to serious illnesses [2] - The company will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco, CA [1] - Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation; and CRB-913, a CB1 inverse agonist for obesity treatment [2]

U.S. stock futures rose in the first full trading week of the year on Monday after closing mixed on Friday. Futures of major benchmark indices were higher.Over the weekend, the U.S. struck Venezuela and toppled Nicolás Maduro‘s regime. On Saturday, President Donald Trump announced that U.S. oil companies are preparing to invest billions in Venezuela's oil industry, after the removal of President Maduro.The objective, as stated by Trump, is to restore Venezuela's dilapidated oil infrastructure and kick-start ...

Group 1 - Hong Kong's biotech fundraising momentum is projected to continue into 2026, driven by licensing deals and strong post-IPO trading, indicating renewed investor confidence in China's drug developers [1][2] - The domestic innovation sector is entering a harvest phase, with Chinese innovative drugs increasingly expanding into overseas markets, making biopharmaceutical stocks attractive [2] - Analysts highlight that while capital is returning to the biotech sector, it also emphasizes the underlying risks associated with the industry [3] Group 2 - Biotech is characterized as a high-risk, cash-intensive sector, with expectations of falling US interest rates and declining borrowing costs likely to attract more investors [4] - Several companies are in the IPO pipeline, including CSPC Innovation Pharmaceutical, which has commercialized two antibody drugs and two mRNA vaccines, and has a pipeline of 15 drug candidates [4] - Under Chapter 18A, companies like Jingze Biopharmaceutical and InventisBio have filed for Hong Kong IPOs, targeting various therapeutic areas, while Frontera Therapeutics aims to list as a clinical-stage gene therapy company [5] - Guangzhou Novaken Pharm is also an 18A applicant, developing drugs across multiple therapeutic areas, and the success of recent healthcare IPOs is encouraging more companies to seek fundraising in Hong Kong [6]

Shares of GH Research PLC (NASDAQ:GHRS) rose sharply in pre-market trading after the company announced it will provide an update on its FDA IND status and Phase 3 program for GH001 in treatment-resistant depression.GH Research shares jumped 18.1% to $15.64 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersMKDWELL Tech Inc (NASDAQ:MKDW) surged 61.2% to $0.27 in pre-market trading. MKDWELL Tech agreed to repurchase 34,580,000 ordinary shares at a price of $0.203/ ...